0001140361-15-023698.txt : 20150609
0001140361-15-023698.hdr.sgml : 20150609
20150609172632
ACCESSION NUMBER: 0001140361-15-023698
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150605
FILED AS OF DATE: 20150609
DATE AS OF CHANGE: 20150609
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO BIOSCIENCES INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ANDO DALE G
CENTRAL INDEX KEY: 0001202278
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 15921744
MAIL ADDRESS:
STREET 1: C/O CELL GENESYS INC
STREET 2: 500 FORBES BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc1.xml
FORM 4
X0306
4
2015-06-05
0
0001001233
SANGAMO BIOSCIENCES INC
SGMO
0001202278
ANDO DALE G
C/O SANGAMO BIOSCIENCES INC.
POINT RICHMOND TECH CNTR, 501 CANAL BLVD
RICHMOND
CA
94804
0
1
0
0
VP, Therapeutic Dev. & CMO
Common Stock
2015-06-05
4
M
0
15000
3.45
A
111763
D
Common Stock
2015-06-05
4
S
0
15000
12.2929
D
96763
D
Employee Stock Option (Right to Buy)
3.45
2015-06-05
4
M
0
15000
0
A
2018-12-09
Common Stock
15000
50798
D
The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 23, 2014.
Includes 11,666, 15,333 and 25,000 shares subject to RSUs granted on December 6, 2012, December 12, 2013 and December 11, 2014 respectively, which will be issued as such units vest in accordance with their terms.
Includes 1,387 shares acquired by the Reporting Person on April 30, 2015 under the Issuer's Employee Stock Purchase Plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.14 to $12.46, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
All shares underlying this option are vested and immediately exercisable.
/s/ Florence Tam, attorney-in-fact
2015-06-09